RedHill Biopharma’s Talicia now covered by Humana’s Part D Plan

RedHill Biopharma (RDHL) announced the coverage of Talicia by Humana’s Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without the requirement for prior therapeutic steps or authorizations, for both treatment-naive and treatment-experienced patients, effective as of January 1. The recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H. pylori infection. The company also announced the publication of new data in The Journal of Clinical Pharmacology describing the foundations for Talicia’s recently FDA-approved label change to a more convenient three-times daily with food dosing routine.